The non-surgical option for vitreoretinal diseases
Ocriplasmin (ThromboGenics) is a first-in-class small molecule delivered through an intravitreal injection that targets fibronectin, laminin, and type IV collagen fibers that adhere the vitreous to the retina. The goal is to create a clean separation of the posterior vitreous cortex and the inner limiting membrane of the retina, thus avoiding a vitrectomy.
